
AMVUTTRA® DELIVERS
RAPID
KNOCKDOWN
The first and only silencer for both ATTR-CM and hATTR-PN, AMVUTTRA suppresses TTR* production at the source.1-4
*The primary source of TTR production is the liver, and TTR knockdown was first measured in the serum at 6 weeks in HELIOS‑B.5,6
Explore the efficacy data for ATTR-CM
Explore the efficacy data for hATTR-PN
Explore AMVUTTRA’s mechanism of action
Learn about the dosing and administration of AMVUTTRA
Learn how to get your patients started with AMVUTTRA
Learn about patient support services
AMVUTTRA is the #1 prescribed treatment for hATTR-PN in adults.5
ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; hATTR-PN=polyneuropathy of hereditary transthyretin-mediated amyloidosis.